Company Description

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.

It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

bioAffinity Technologies, Inc.

Country	United States
Founded	2014
Industry	Diagnostics & Research
Sector	Healthcare
Employees	57
CEO	Maria Zannes

Contact Details

Address: 3300 Nacogdoches Road, Suite 216 San Antonio, Texas 78217 United States
Phone	210 698 5334
Website	bioaffinitytech.com

Stock Details

Ticker Symbol	BIAFW
Exchange	NASDAQ
Stock Type	Warrants
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001712762
CUSIP Number	09076W117
ISIN Number	US09076W1172

Key Executives

Name	Position
Maria Zannes J.D.	Founder, President, Chief Executive Officer and Director
Steven Girgenti	Founder and Executive Chairman of the Board
James Michael Edwards CPA, M.B.A.	Chief Financial Officer
Xavier T. Reveles M.S.	Chief Operating Officer
Dr. William Bauta Ph.D.	Chief Science Officer
Timothy P. Zannes J.D.	Executive Vice President, Secretary and General Counsel
Julie Anne Overton	Director of Communications
Dallas J. Coleman	Vice President of sales
Dr. Gordon Downie M.D., Ph.D.	Chief Medical Officer